Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
This is the company’s first partnership arrangement in China
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
